Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.75
ETRM's Cash to Debt is ranked higher than
56% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. ETRM: 5.75 )
Ranked among companies with meaningful Cash to Debt only.
ETRM' s 10-Year Cash to Debt Range
Min: 1.29  Med: 4.14 Max: N/A
Current: 5.75
F-Score: 2
Z-Score: -28.77
M-Score: -5.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -235.76
ETRM's ROE (%) is ranked lower than
96% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.14 vs. ETRM: -235.76 )
Ranked among companies with meaningful ROE (%) only.
ETRM' s 10-Year ROE (%) Range
Min: -1135.7  Med: -140.32 Max: -77.38
Current: -235.76
-1135.7
-77.38
ROA (%) -133.42
ETRM's ROA (%) is ranked lower than
93% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.22 vs. ETRM: -133.42 )
Ranked among companies with meaningful ROA (%) only.
ETRM' s 10-Year ROA (%) Range
Min: -962.06  Med: -86.74 Max: -60.09
Current: -133.42
-962.06
-60.09
ROC (Joel Greenblatt) (%) -5372.88
ETRM's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. ETRM: -5372.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ETRM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4834.37  Med: -2401.78 Max: -575.02
Current: -5372.88
-4834.37
-575.02
EBITDA Growth (3Y)(%) -23.60
ETRM's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. ETRM: -23.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ETRM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -59.80 Max: -23.6
Current: -23.6
EPS Growth (3Y)(%) -23.20
ETRM's EPS Growth (3Y)(%) is ranked lower than
75% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. ETRM: -23.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ETRM' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.1  Med: -54.90 Max: 41.9
Current: -23.2
-69.1
41.9
» ETRM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ETRM Guru Trades in Q1 2014

Chuck Royce 1,285,000 sh (unchged)
» More
Q2 2014

ETRM Guru Trades in Q2 2014

Chuck Royce 1,060,000 sh (-17.51%)
» More
Q3 2014

ETRM Guru Trades in Q3 2014

Chuck Royce 648,600 sh (-38.81%)
» More
Q4 2014

ETRM Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ETRM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.40
ETRM's P/B is ranked higher than
50% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. ETRM: 3.40 )
Ranked among companies with meaningful P/B only.
ETRM' s 10-Year P/B Range
Min: 3.02  Med: 4.83 Max: 12.3
Current: 3.4
3.02
12.3
Current Ratio 1.85
ETRM's Current Ratio is ranked lower than
68% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. ETRM: 1.85 )
Ranked among companies with meaningful Current Ratio only.
ETRM' s 10-Year Current Ratio Range
Min: 1.69  Med: 3.37 Max: 9.46
Current: 1.85
1.69
9.46
Quick Ratio 1.69
ETRM's Quick Ratio is ranked lower than
59% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ETRM: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
ETRM' s 10-Year Quick Ratio Range
Min: 1.56  Med: 3.37 Max: 9.46
Current: 1.69
1.56
9.46

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.17
ETRM's Price/Net Cash is ranked higher than
81% of the 105 Companies
in the Global Medical Devices industry.

( Industry Median: 14.23 vs. ETRM: 5.17 )
Ranked among companies with meaningful Price/Net Cash only.
ETRM' s 10-Year Price/Net Cash Range
Min: 2  Med: 5.79 Max: 84.53
Current: 5.17
2
84.53
Price/Net Current Asset Value 3.88
ETRM's Price/Net Current Asset Value is ranked higher than
71% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 6.53 vs. ETRM: 3.88 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ETRM' s 10-Year Price/Net Current Asset Value Range
Min: 1.96  Med: 4.93 Max: 70.1
Current: 3.88
1.96
70.1
Price/Tangible Book 3.10
ETRM's Price/Tangible Book is ranked higher than
59% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. ETRM: 3.10 )
Ranked among companies with meaningful Price/Tangible Book only.
ETRM' s 10-Year Price/Tangible Book Range
Min: 1.88  Med: 4.15 Max: 44.22
Current: 3.1
1.88
44.22
Earnings Yield (Greenblatt) (%) -162.55
ETRM's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ETRM: -162.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ETRM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -191.2  Med: 0.00 Max: 0
Current: -162.55
-191.2
0

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:BY8N.Germany,
EnteroMedics Inc was incorporated in Minnesota on December 19, 2002 and later reincorporated in Delaware on July 22, 2004. It is a medical device company with approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries that recognize the European CE Mark. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's proprietary neuroblocking technology, VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company's initial product, the Maestro Rechargeable System uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has regulatory approval to sell its product in Australia, the European Economic Area and other countries that recognize the European CE Mark and do not have any other source of revenue. The Company relies on third-party manufacturers and suppliers for the production of its Maestro Rechargeable System. The Company competes in the market for obesity treatment with surgical obesity procedures and various devices used to implement neurostimulation and gastric stimulation systems. The Company also competes against the manufacturers of pharmaceuticals that are directed at treating obesity. The Company's opeartors include: Roche, GlaxoSmithKline, Arena Pharmaceuticals, Inc., VIVUS, Inc. and Orexigen Therapeutics, Inc. The Company also competes with several private early-stage companies developing neurostimulation devices for application to the gastric region and related nerves for the treatment of obesity. The Company has 32 national stage patent applications, including applications in Australia, China, India, Europe and Japan, one granted Chinese application and one granted application in Japan. In addition, the Company is the exclusive licensee to three U.S. patents owned by the Mayo Foundation for Medical Education and Research, which are unrelated to the Company's VBLOC therapy. Maestro Rechargeable System is regulated by the FDA as a medical device under the Federal Food, Drug, and Cosmetic Act (FFDCA) and the regulations promulgated under the FFDCA.
» More Articles for NAS:ETRM

Headlines

Articles On GuruFocus.com
Kevin Douglas Bets on EnteroMedics; Popeyes and AMERCO Top Estimates May 28 2015 
Canaccord Genuity Remains Bullish on EnteroMedics Following Q4 Earnings Feb 19 2015 
Analysts Are Bullish On EnteroMedics Following FDA Approval Of Obesity Treatment Jan 16 2015 
EnteroMedics Inc. Reports Operating Results (10-K) Mar 07 2011 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 08 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 06 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 16 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 07 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call Jul 30 2015
EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call Jul 30 2015
EnteroMedics Announces the Launch of vBloc® Access Jul 27 2015
EnteroMedics Announces the Launch of vBloc® Access Jul 27 2015
EnteroMedics Announces Publication of 18 Month ReCharge Clinical Study Data in the Journal of... Jul 16 2015
EnteroMedics Announces Publication of 18 Month ReCharge Clinical Study Data in the Journal of... Jul 16 2015
ENTEROMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 08 2015
EnteroMedics Inc. Announces Closing of $16.0 Million Public Offering of Common Stock and Warrants Jul 08 2015
EnteroMedics Inc. Announces Closing of $16.0 Million Public Offering of Common Stock and Warrants Jul 08 2015
ENTEROMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Jul 07 2015
EnteroMedics Inc. (ETRM) in Focus: Stock Jumps 8.8% - Tale of the Tape Jul 07 2015
EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants Jul 07 2015
EnteroMedics Inc. Announces Pricing of $16.0M Public Offering of Common Stock and Warrants, 32M... Jul 07 2015
EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants Jul 07 2015
ENTEROMEDICS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events,... Jul 06 2015
EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants Jul 06 2015
EnteroMedics Inc. Announces Termination of Public Offering of Common Stock and Warrants Jul 06 2015
EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants Jul 06 2015
EnteroMedics Inc. Announces Termination of Public Offering of Common Stock and Warrants Jul 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK